Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 and AK112 in HER2-Altered Advanced NSCLC
NCT07489703Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of trastuzumab rezetecan, ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecanivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07489703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07489703.